A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of ‘personalized’ therapies for rare diseases; but pathways to implementation and access are urgently needed.
- Rebecca Schuele
- Matthis Synofzik
- Annemieke Aartsma-Rus
